Amyloid diseases affect over a billion people worldwide and are reaching epidemic levels as lifespans increase. There are over 50 known human amyloid diseases involving different proteins and peptides. Amyloid diseases are due to protein misfolding — normal proteins change structure and ultimately form amyloid fibrils and plaques. Amyloid is also associated with multidrug-resistant bacterial infections and medical implants.

AltPep discovered α-sheet, a new, nonstandard protein structure, associated with toxicity in computer simulations of amyloid proteins and then designed de novo nontoxic α-sheet peptides to be complementary to the α-sheet structure in toxic species. Outcome: Proprietary platform targeting toxic species for both early diagnostics and disease-modifying therapeutics.
AltPep’s patented technology provides a groundbreaking platform for targeting amyloid diseases and improving human health.
Initial AltPep targets:

• Anti-biofilm therapies and coatings
• Early diagnostic for Alzheimer’s Disease (AD)
• Disease-modifying therapeutics for Alzheimer's Disease

Founder: Valerie Daggett, PhD
Management:

• Kurt Becker, JD
• Patrik Edenholm, MA, MPA, JD
• Charles Horne, MBA, CPA